515 related articles for article (PubMed ID: 23690482)
1. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
[TBL] [Abstract][Full Text] [Related]
2. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
3. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
[TBL] [Abstract][Full Text] [Related]
4. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of ADAM17 in cord blood stem cell-derived CD16
Valipour B; Mohammadi SM; Abedelahi A; Charoudeh HN
Hum Immunol; 2024 May; 85(3):110769. PubMed ID: 38429146
[TBL] [Abstract][Full Text] [Related]
6. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).
Romee R; Foley B; Lenvik T; Wang Y; Zhang B; Ankarlo D; Luo X; Cooley S; Verneris M; Walcheck B; Miller J
Blood; 2013 May; 121(18):3599-608. PubMed ID: 23487023
[TBL] [Abstract][Full Text] [Related]
7. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
8. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
9. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
Sarhan D; Brandt L; Felices M; Guldevall K; Lenvik T; Hinderlie P; Curtsinger J; Warlick E; Spellman SR; Blazar BR; Weisdorf DJ; Cooley S; Vallera DA; Önfelt B; Miller JS
Blood Adv; 2018 Jun; 2(12):1459-1469. PubMed ID: 29941459
[TBL] [Abstract][Full Text] [Related]
10. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD16 (Fc gamma RIII) expressed by human natural killer (NK) cells.
Silla LM; Chen J; Zhong RK; Whiteside TL; Ball ED
Br J Haematol; 1995 Apr; 89(4):712-8. PubMed ID: 7772507
[TBL] [Abstract][Full Text] [Related]
12. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
[TBL] [Abstract][Full Text] [Related]
13. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
[TBL] [Abstract][Full Text] [Related]
14. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.
Eckel AM; Cherian S; Miller V; Soma L
Cytometry B Clin Cytom; 2020 Mar; 98(2):174-178. PubMed ID: 31622025
[TBL] [Abstract][Full Text] [Related]
15.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
16. Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia.
Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W
Cancer Lett; 2023 Apr; 558():216103. PubMed ID: 36805460
[TBL] [Abstract][Full Text] [Related]
17. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
18. CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect.
Lu X; Kondo Y; Takamatsu H; Ohata K; Yamazaki H; Takami A; Akatsuka Y; Nakao S
Eur J Haematol; 2008 Jul; 81(1):18-25. PubMed ID: 18363874
[TBL] [Abstract][Full Text] [Related]
19. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
Vasu S; He S; Cheney C; Gopalakrishnan B; Mani R; Lozanski G; Mo X; Groh V; Whitman SP; Konopitzky R; Kössl C; Bucci D; Lucas DM; Yu J; Caligiuri MA; Blum W; Adam PJ; Borges E; Rueter B; Heider KH; Marcucci G; Muthusamy N
Blood; 2016 Jun; 127(23):2879-89. PubMed ID: 27013443
[TBL] [Abstract][Full Text] [Related]
20. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]